术前P2Y12受体抑制剂种类与停药时间对CABG出血的影响
单中心研究纳入299例末次P2Y12抑制剂后7天内行CABG(伴或不伴瓣膜干预)的患者,评估计算红细胞丢失与BARC-4出血。83%患者在末次服药48小时内手术;氯吡格雷组计算失血量低于普拉格雷或替格瑞洛组,BARC-4出血总体发生率为45%且组间存在差异。停药超过48小时可显著减少失血与BARC-4出血。
要点
- 普拉格雷或替格瑞洛在CABG前24小时内暴露,失血与BARC-4出血高于氯吡格雷
- 停药超过48小时较0至24小时可大幅减少计算失血与BARC-4出血
- 血流动力学稳定、心肌未受威胁时,应严格遵循2017指南的停药等待推荐
核心结论
- 与氯吡格雷相比,CABG前24小时或更短时间内暴露于普拉格雷或替格瑞洛会增加计算失血量和BARC-4出血。
- 停药超过48小时可在所有P2Y12受体抑制剂中大幅减少计算失血量和BARC-4出血,单中心数据支持在条件允许时严格遵循2017指南。
研究设计与样本
- 单中心研究,纳入299例在末次P2Y12受体抑制后不到7天行CABG(伴或不伴瓣膜干预)的患者。
- 评估指标为计算红细胞丢失和Bleeding Academic Research Consortium 4型(BARC-4)出血。
主要发现
- 83%的患者在末次服药后不到48小时接受CABG。
- 氯吡格雷组计算失血量为1063 mL(690至1394 mL),低于普拉格雷组的1351 mL(876至1829 mL)和替格瑞洛组的1330 mL(994至1691 mL),P < .001。
- 135例(45%)发生BARC-4出血,各组发生率存在差异(P = .015),普拉格雷组显著高于氯吡格雷组。
- 多变量线性回归中,EuroSCORE II、阿司匹林剂量、体外循环时间、停药时间和P2Y12受体抑制剂种类与红细胞丢失显著相关。
- 与0至24小时相比,术前停药超过48小时使计算失血量减少37%至48%、BARC-4出血减少58%至71%,幅度因P2Y12受体抑制剂种类而异。
关键数值与推荐
- 指南推荐术前标准化等待时间至少为:替格瑞洛3天、氯吡格雷5天、普拉格雷7天。
- BARC-4出血总体发生率为45%(135例)。
临床怎么用
- CABG术前应关注P2Y12受体抑制剂的种类与末次服药时间,评估出血风险。
- 在血流动力学稳定、心肌未受威胁时,尽量保证停药超过48小时,并遵循2017指南推荐的3、5、7天等待时间。
局限性
- 为单中心数据,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite recommendations for standardized preoperative waiting of at least 3, 5, and 7 days for ticagrelor, clopidogrel, and prasugrel, respectively, there is still substantial interinstitutional variation in preoperative discontinuation of dual antiplatelet therapy in patients needing coronary artery bypass grafting (CABG). METHODS: In 299 patients undergoing CABG with or without valve intervention less than 7 days after last P2Y12 receptor inhibition, this study evaluated calculated red blood cell loss and Bleeding Academic Research Consortium type 4 (BARC-4) bleeding. RESULTS: A total of 83% of patients underwent CABG less than 48 hours after last drug intake. Calculated blood loss was lower in patients taking clopidogrel as compared with prasugrel or ticagrelor (1063 mL [690 to 1394 mL] vs 1351 mL [876 to 1829 mL] vs 1330 mL [994 to 1691 mL]; P < .001). Overall, 135 (45%) patients sustained BARC-4 bleeding; the incidence differed among the groups (P = .015) and was significantly higher in prasugrel-treated patients, as compared with clopidogrel-treated patients. In multivariable linear regression analysis, European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), aspirin dose, cardiopulmonary bypass time, drug withdrawal time, and type of P2Y12 receptor inhibitor were significantly associated with red blood cell loss. Compared with 0 to 24 hours, a period of more than 48 hours of preoperative discontinuation substantially reduced calculated blood loss by 37% to 48% and BARC-4 bleeding by 58% to 71%, depending on the P2Y12 receptor inhibitor. CONCLUSIONS: Exposure to prasugrel and ticagrelor 24 hours or less before CABG increases both calculated blood loss and BARC-4 bleeding as compared with clopidogrel. Although discontinuation for longer than 48 hours substantially reduced calculated blood loss and BARC-4 bleeding across all P2Y12 receptor inhibitors, our single-center data further support strict adherence to the 2017 guidelines whenever justified by stable hemodynamics and nonjeopardized myocardium.
引用
- Voetsch A, Pregartner G, Berghold A, et al. How Do Type of Preoperative P2Y12 Receptor Inhibitor and Withdrawal Time Affect Bleeding? Ann Thorac Surg. 2020. PMID: 32565086. doi:10.1016/j.athoracsur.2020.04.126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。